Document Detail


Presence of coronary plaques in patients with nonalcoholic fatty liver disease.
MedLine Citation:
PMID:  20093511     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To evaluate the relationship between nonalcoholic fatty liver disease (NAFLD) and coronary artery disease (CAD) and to define determinants of CAD in patients with or without metabolic syndrome. MATERIALS AND METHODS: This study was approved by the local ethics committee; informed consent was obtained. Twenty-nine subjects (mean age, 53 years +/- 7 [standard deviation]) with low to intermediate risk for CAD and with fatty liver were included. Thirty-two sex- and age-matched individuals without NAFLD served as controls. CAD was defined as a stenosis of more than 50% in at least one major coronary artery. Fatty liver was assessed by means of an attenuation of -10 HU or higher (calculated as liver attenuation minus spleen attenuation) by using computed tomography (CT), coronary plaques and stenosis by using CT coronary angiography, and biomarkers of insulin resistance, lipotoxicity, systemic inflammation, and oxidant and antioxidant status. A logistic regression analysis was performed to study multivariable associations. RESULTS: When compared with controls, NAFLD patients showed a higher prevalence of calcified and noncalcified coronary plaques (67% vs 34% and 52% vs 29%, respectively; both P < .001), higher prevalence of nonobstructive coronary stenosis (34% vs 14%; P < .008), higher homeostasis model assessment of insulin resistance (3.8 epsilonU/mL +/- 3.6 vs 2.6 epsilonU/mL +/- 3.2; P < .005) and higher triglyceride levels (208 mg/dL +/- 87 vs 148 mg/dL +/- 70; P < .005). Fatty liver proved to be a strong predictor of coronary atherosclerosis (odds ratio [OR], 2; P < .04), independent of indicators for metabolic syndrome (OR, 1.2; P > .2) and C-reactive protein levels (OR, 0.7; P > .4). CONCLUSION: Patients with NAFLD, even without metabolic syndrome, are at high risk for atherosclerosis. Assessment of NAFLD may be helpful for cardiovascular risk stratification.
Authors:
Nimer Assy; Agness Djibre; Raymond Farah; Maria Grosovski; Alon Marmor
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Radiology     Volume:  254     ISSN:  1527-1315     ISO Abbreviation:  Radiology     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-22     Completed Date:  2010-02-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0401260     Medline TA:  Radiology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  393-400     Citation Subset:  AIM; IM    
Copyright Information:
(c) RSNA, 2010.
Affiliation:
Liver Unit, Ziv Medical Centre, Box 1008, Safed 13100, Israel. assy.n@ziv.health.gov.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Biological Markers / analysis
Case-Control Studies
Contrast Media
Coronary Angiography / methods*
Coronary Artery Disease / complications*,  radiography*
Fatty Liver / complications*,  radiography*
Female
Humans
Iopamidol / analogs & derivatives,  diagnostic use
Logistic Models
Male
Middle Aged
Prevalence
Prospective Studies
Risk Assessment
Risk Factors
Tomography, X-Ray Computed / methods*
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Contrast Media; 62883-00-5/Iopamidol; 78649-41-9/iomeprol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cardiac CT angiography for the diagnosis of mitral valve prolapse: comparison with echocardiography1...
Next Document:  Coronary MR imaging: effect of timing and dose of isosorbide dinitrate administration.